ATP citrate-lyase

CAT # Sunan samfur Bayani
Saukewa: CPD3611 Saukewa: SB-204990 SB-204990 shine prodrug na m ATP citrate-lyase inhibitor SB-201076. SB-204990, lokacin da aka ba da baki ga berayen, an nutsar da shi a cikin tsarin wurare dabam dabam, an dawo da matakan da suka dace na SB-201076 a cikin hanta. SB-204990 (25 mg/kg a kowace rana) kuma ya rage matakan cholesterol na plasma (har zuwa 23%) da matakan triglyceride (har zuwa 38%) a cikin kare, wanda zai fi dacewa rage ƙarancin lipoprotein mai yawa idan aka kwatanta da babban cholesterol na lipoprotein mai yawa. matakan. SB-204990 yana da mahimmancin enzyme a cikin sarrafa kayan da aka samar don haɓakar lipid de novo da yuwuwar manufar enzyme don shiga tsakani na hypolipidaemic.
da

Tuntube Mu

Tambaya

Sabbin Labarai

  • Manyan Abubuwa 7 A cikin Binciken Magunguna A cikin 2018

    Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

    Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

  • ARS-1620: Sabuwar mai hanawa don KRAS-mutant cancers

    ARS-1620: Sabuwar mai hanawa don K ...

    A cewar wani binciken da aka buga a cikin Cell, masu bincike sun kirkiro wani takamaiman mai hanawa don KRASG12C mai suna ARS-1602 wanda ya haifar da koma baya a cikin mice. "Wannan binciken yana ba da shaida a cikin vivo shaida cewa mutant KRAS na iya zama ...

  • AstraZeneca yana karɓar haɓakar tsari don magungunan oncology

    AstraZeneca yana karɓar haɓaka tsari don ...

    AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

WhatsApp Online Chat!